Clinical trial · no report yet · Phase 2
PALMIRA
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
- NCT03809988 ↗
- Completed
- MedSIR
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 15 | |
| YouTube | 7 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- Palbociclib; Endocrine therapy
- Arms
- Interventional Arm (Arm A) · Experimental
- Control Arm (Arm B) · Active comparator
- Enrollment
- 198
- Primary outcomes
- PFS (Progression-free survival)
- Sponsor
- MedSIR with Pfizer
- Start
- Apr 5, 2019
- Primary completion
- Nov 30, 2022
- Results posted
- No
- Registry record
- NCT03809988 · updated Sep 7, 2023
Publications
linked from the registry- Llombart-Cussac A, Harper-Wynne C, Perello A, Hennequin A, Fernandez-Ortega A, Colleoni M, Marin S, Quiroga V, Medioni J, Iranzo V, Wheatley D, Del Barco Berron S, Anton A, Dobi E, Ruiz-Borrego M, Alcala-Lopez D, Perez-Escuredo J, Antonarelli G, Sampayo-Cordero M, Perez-Garcia JM, Cortes J. Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. J Clin Oncol. 2025 Jun 20;43(18):2084-2093. doi: 10.1200/JCO-24-01865. Epub 2025 Apr 28. PubMed 40294349